Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3097MR)

This product GTTS-WQ3097MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3097MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4576MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ15685MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ8607MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ5443MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ11464MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ13816MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ5856MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ15157MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW